Tag: pembrolizumab)

A retrospective study of 517 patients found that mid-treatment MRI response strongly predicts pathologic complete response in triple-negative breast cancer, ...

A case report in BMC Gastroenterology describes sustained hepatitis B surface antigen seroclearance in a patient with esophageal and gastric ...

A case report documents nine months of stable disease in a patient with metastatic GIST treated with pembrolizumab after failing ...

Clinicians report an 89-year-old patient who developed an atypical Merkel cell carcinoma at an actinic keratosis site following photodynamic therapy.

Researchers found RPL22 mutations in 42% of undifferentiated/dedifferentiated endometrial carcinoma samples and showed in cell and xenograft models that the ...

A case report details the diagnostic and therapeutic challenges of managing immune checkpoint inhibitor myocarditis in a patient with coexisting ...

Researchers have formulated a GMP-quality kit for preparing a zirconium-89 labelled pembrolizumab PET imaging agent, with preclinical studies supporting safety ...

A case report describes arginine vasopressin deficiency that emerged only after glucocorticoid therapy unmasked pembrolizumab-induced hypophysitis in a man with ...

An AI-based digital pathology assessment of PD-L1 identified metastatic triple-negative breast cancer patients with longer progression-free survival on pembrolizumab in ...

A case report documents curative lung resection 144 days after a patient survived grade 4 immune checkpoint inhibitor-associated myocarditis during ...

A case report in Oncoscience details a patient with metastatic lung cancer who developed severe Coombs-negative hemolytic anemia after pembrolizumab ...

A 78-year-old woman developed hyperactive delirium with hallucinations and persecutory delusions during pembrolizumab therapy, and her symptoms fully resolved after ...

A real-world cohort study of 136 patients aged 65 and older found high rates of hospitalization and immune-related toxicity with ...

A case report details how a 46-year-old HIV-negative woman with idiopathic CD4+ lymphocytopenia developed progressive multifocal leukoencephalopathy and died despite ...

Phase 3 trial results presented at ESMO 2026 show that adding personalized mRNA vaccine intismeran to pembrolizumab reduces melanoma recurrence ...

The Phase 3 DESTINY-Lung04 trial reports that first-line single-agent trastuzumab deruxtecan significantly improved progression-free survival and response rates versus pembrolizumab ...

A single-patient case report documents delayed toxic epidermal necrolysis after six cycles of pembrolizumab and enfortumab vedotin for metastatic urothelial ...

A prespecified interim analysis of the phase 3 HARMONi-2 trial shows ivonescimab achieved median overall survival of 30.8 months versus ...

A network meta-analysis of six randomized trials in 5,838 patients finds that pembrolizumab plus belzutifan offers the strongest protection against ...

A single-case report describes improved fitness for surgery, a reported ypT0N0 pathological response with a stated pathology-verification caveat, and no ...